Anebulo Pharmaceuticals, Inc.
NASDAQ:ANEB
Overview | Financials
Company Name | Anebulo Pharmaceuticals, Inc. |
Symbol | ANEB |
Currency | USD |
Price | 1.596 |
Market Cap | 41,376,421 |
Dividend Yield | 0% |
52-week-range | 0.8 - 3.3 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. Joseph F. Lawler M.D., Ph.D. |
Website | https://www.anebulo.com |
An error occurred while fetching data.
About Anebulo Pharmaceuticals, Inc.
Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing and commercializing treatments for people suffering from acute cannabinoid intoxication and substance addiction. Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist to treat cannabinoid intoxication and overdose. The company was incorporated in 2020 and is based
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD